Vaccine research & innovation


Published on

  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Vaccine research & innovation

  1. 1. Vaccine Research & Innovation 2010 Exploring global opportunities in vaccine research and development 2nd – 3rd September 2010,BSG House, London, UK BOOK NOW! Key Speakers Guido Grandi, Senior Project Leader, Novartis Vaccines and Diagnostics Dr Alex Kudrin, Medical Assessor, Biological PLAT, MHRA Dr Bassam Hallis, General Project Manager, Centre for Emergency Preparedness and Response, Health Protection Agency Dr Jon Heinrichs, Senior Research Fellow, Vaccine Basic Research, Merck Dr Carmen Giefing, Group Leader, Antigen Identification - Molecular Microbiology, Intercell Dr David Kirke, Associate Director of Regulatory Affairs, ERA Consulting Dr Barbara Guinn, Cancer Sciences Division, University of Southampton Jean Marc Balloul, New Venture Development Director, Transgene Lior Carmon, Founder & CEO, Vaxil Biotherapeutics Silver Sponsor Driving the Industry Forward | Media Partners Organised by To Book Call: +44 (0) 20 7336 6100 |
  2. 2. Conference Introduction Vaccine Research & Innovation 2010 2nd – 3rd September 2010 Dear Colleague, Silver Sponsor: Increasing use of novel technologies has boosted the vaccines industry worldwide. Encorium is a full service CRO with experience in more than 30 Recent technological breakthroughs in vaccine research, manufacturing and countries worldwide. With expertise and investigator networks we have delivery, promise a bright future for the new generation of vaccines, particularly for serviced successfully over 20 clients and recruited over 55,000 subjects/ chronic conditions such as cancer, auto-immune diseases and nicotine addiction. patients in pediatric, adult and elderly populations for prophylactic and According to Visiongain’s recent report, The Global Vaccines Market, 2008-2023, therapeutic vaccine. By establishing a global CRO network Encorium is strengthening its offerings in vaccine development. Encorium ensures efficiency in therapeutic vaccines will significantly expand the vaccines market contributing to clinical trial design and execution. Having been trusted the conduct of some of the rapid revenue growth during the period 2008 to 2023. The cancer vaccine market, largest vaccine studies performed we understand that our success is rooted in our led by cervical cancer vaccines, is presently one of the most lucrative areas for clients success and we are committed to becoming a world leading vaccine CRO. vaccine manufacturers. Advances are also being made in almost all adjunct areas of vaccine research, such as the mode of delivery, use of combination vaccines, For further information please visit vaccine adjuvant, and vaccine manufacturing. Media Partners: Our Vaccine Research & Innovation conference is designed to implement is the leading industry-sponsored portal for successful strategies and innovative technologies to develop more effective the pharmaceutical sector. Supported by most of the leading vaccines. Gain insights through industry led case studies and discussions with pharmaceutical corporations, provides dynamic real-time news, key decision markers from the vaccines sector. Network and collaborate with features, events listings and international jobs to industry professionals across Europe global professionals to keep up-to-date with future trends and exploring business and the US. opportunities at the two-day event. For further information please email: By attending this conference you will gain insights on: BIOTECHNOLOGY EUROPE is owned by BIOTECHNOLOGY • Overcoming challenges to cancer vaccine development WORLD. It is based and located in Warsaw, Poland. Biotechnology World was founded in 2007 to provide the world’s biotech • Evaluating the immune response to combination vaccines and pharma information and market to make it universally accessible and useful • Accelerating new vaccine introduction in the developing world for scientific and business processes. Its first step to fulfilling that mission was building the BIOTECHNOLOGY EUROPE platform that will allow a quick spread of • Monitoring High sensitivity T cell immune mechanism of novel vaccines, gene information in different channels. BIOTECHNOLOGY EUROPE offers companies therapy, protein based drugs completed internet public relations, publication and marketing solutions. One of the mains goals of BIOTECHNOLOGY EUROPE is to integrate the Biotech and Pharma • ssessing the key immunological observations on clinical development of A Sector in Europe to global biotechnology, pharmaceutical and life science activities. pandemic infl uenza A (H1N1) vaccines For further information please visit • Examining the safety challenges on new vaccine introduction Future Pharmaceuticals has forged powerful relationships with Driving the Industry Forward | • mplementing strategies for manufacturing and purification of conjugate I key industry leaders to provide a platform for successful brand vaccines recognition, and for senior decision-makers to have the means to procure and plan implementation strategies based on the topics covered. Positioned to • Good supply chain management practices for vaccine distribution be an authoritative resource within top pharma companies as well as small, specialty, I look forward to meeting you at the conference and biotech, Future Pharmaceuticals magazine is geared to create a deep penetration into a highly targeted and responsive audience, bridging the gap between the Best regards industries’ top issues and the solutions top-tier vendors can provide. For further information please visit: InPharm is the online platform for exclusive pharmaceutical news, Maninder Paul comment, contracts, services, jobs and events and is home to Conference Producer, Pharmafile and Pharmafocus. For further information please visit: ‘Pharma Connections Worldwide® is the leading professional business networking website focused in the Pharmaceutical, Biotechnology Who will be there? and Life Sciences research industry. Our goal is to provide a conduit for delivery of premiere content coupled with the right clientele in order to facilitate business Presidents, Chief Executives, VPs, Global Heads, Scientific Advisors, Therapeutic Area development opportunities among industry professionals responsible for making key decisions Heads, in: in a global marketplace. ‘ For further information please visit: • Vaccine equipment and manufacturing • Vaccine application development • Vaccinology and molecular biology • Cell line engineering • Proteomics, recombinant protein/DNA biotechnology • Infectious disease R&D Sponsorship and exhibition opportunities: • In-licensing and out-licensing • Pharmacovigilance and safety testing This event offers a unique opportunity to meet and do business with some • Regulatory affairs of the key players in the pharmaceutical and biotech industries. If you have a • Strategic product development service or product to promote, you can do so at this event by: • External research • Hosting a networking drinks reception • Manufacturing/production • Chemistry manufacturing and controls (CMC) • Taking an exhibition space at the conference • Procurement & purchasing • Cold chain supply and lyophilisation • Advertising in the delegate documentation pack • Strategic alliances • Providing branded bags, pens, gifts, etc. • Clinical product resourcing • Supply outsourcing project management If you would like more information on the range of sponsorship or exhibition • Contract management possibilities for visiongain's Vaccine Research & Innovation Conference, please • Process development contact us: • Business development • Drug discovery & delivery Ronald Magali, +44 (0)20 7549 9934 • Patent law • Investment and venture capital
  3. 3. Day 1 Vaccine Research & Innovation 2010 Thursday 2nd September 2010 09:30 Registration and refreshments 12:50 Networking lunch 13.50 Leveraging a CRO in accelerating 10:00 Opening address from the chair vaccine development • Agility in a regulated environment 10:10 Regulatory challenges in the approval process • Experiences for novel vaccine adjuvants • Efficiencies • Regulation and evaluation process of new adjuvants in vaccines epresentative R • ifferences in the global regulatory requirements and overcoming D Encorium these challenges • ngaging with regulators and contributing to the evolution of E regulatory framework 14:10 Development of a 15-valent pneumococcal - conjugate vaccine • ntegrating your global regulatory strategy and product I development plan • lobal epidemiological trends following pneumococcal-conjugate G vaccine introduction r David Kirke D Associate Director - Regulatory Affairs • evelopment of a polysaccharide-conjugate vaccine with expanded D serotype coverage ERA Consulting • valuation of vaccine immunogenicity in rabbit and infant-monkey E model systems 10:50 Evaluating the immune response to r Jon Heinrichs D combination vaccines Senior Research Fellow, Vaccine Basic Research Merck • igh sensitivity T cell immune monitoring of novel vaccines, H gene therapy, protein based drugs • mmune monitoring during pre clinical and clinical trials I 14:50 Afternoon refreshments to detect adverse immune reactions to gene therapy and protein based drugs early r Thomas O Kleen D 15:10 Regulatory and clinical development challenges with Director, Business and Technology Development cancer vaccines Cellular Technology • Current status of new therapeutic vaccines development; • Clinical lessons and learning’s from recent product development; • egulatory principles and guidelines on clinical development of new R 11:30 Morning refreshments therapeutic vaccines r Alex Kudrin D 11:50 CMC and pre-clinical development of a cellular Medical Assessor, Biological PLAT tumour vaccine product MHRA • urrent-generation high-throughput sequencing C • Establishing new assays for high-throughput screening 15:50 Challenges to cancer vaccine development • ptimised system for rapid generation of localisation and affinity O • verview of the main immune responses O purification-tagged mammalian stable cell lines • Identifying targets for immune therapy • Stabilisation of cell lines • New vaccine development and current clinical trials r Klaus Kühlcke D r Barbara Guinn D Eufets Cancer Sciences Division University of Southampton 12.10 Development of avian cell lines dedicated to vaccines manufacturing 16:30 Closing remarks from the chair • Human vaccine (Flu, Flavivirus, Recombinant Poxvirus) • Veterinary vaccine • Therapeutic proteins 16:40 Networking drinks ean Marc Balloul J Take your discussions further and build new New Venture Development Director relationships in a relaxed and informal setting. Transgene Due to unforeseen circumstances the programme may change and visiongain reserves the right to alter the venue and/or speakers c Copyright visiongain Ltd, 2010
  4. 4. Day 2 Vaccine Research & Innovation 2010 Friday 3rd September 2010 09:30 Registration and refreshments 13:10 Networking lunch 10:00 Opening address from the chair 14:10 Case study: Developing the next generation of therapeutic vaccines 10:10 Development of a pneumococcal vaccine comprising CASE STUDY T he case study will feature novel, therapeutic vaccines for the treatment highly conserved proteins of cancer and key intracellular pathogens via specific manipulation and • Discovery of a novel class of highly conserved vaccine antigens augmentation of the patient cellular immune responses. • pproach for new-generation vaccines is the use of nonpolysaccharide A ior Carmon L antigens that are conserved among pneumococcal strains Founder & CEO • hanging epidemiology of pneumococcal infection C Vaxil Biotherapeutics • Immunological considerations and correlates r Carmen Giefing D Group Leader, Antigen Identification - Molecular Microbiology 14:50 Surface proteome analysis as a fast-track to Intercell vaccine discovery • Stripping away cell-surface proteins • Mass-spectrometry and in silico surfome analysis 10:50 From trial and error to rational design of adjuvant vaccines • Identification and validation of new targets for group A Streptococcus • Adjuvant need not induce side effects: A different concept uido Grandi G Senior Project Leader • ISCOM, adjuvant for newborns and elderly Novartis Vaccines and Diagnostics • Antigen sparing an essential aspect • Broadening of immune response ror Morein B 15:30 Afternoon refreshments Department of Medical Sciences, Virology, Uppsala University Chairman of the Scientific Advisory Board, Isconova 15.50 Vaccine Development of HIV-1 vaccines inducing protective T cell responses 11:30 Morning refreshments • Design and pre-clinical evaluation • Towards an HIV T cell-based vaccine • Strategies eliciting HIV-1-specific T cell responses 11:50 Case Study: Key immunological observations on • Natural proteins as vaccine antigens clinical development of pandemic influenza A r Tomas Hanke D (H1N1) vaccines Reader in Immunology, Group Head/PI Supervisor, CASE STUDY r Bassam Hallis D HIV-1 Vaccine Development General Project Manager Weatherall Institute of Molecular Medicine Centre for Emergency Preparedness and Response Health Protection Agency 16.30 Accelerating new vaccine introduction in the developing world • eeting the challenges in introducing new vaccines: Logistics, M 12:30 Vaccine development & early clinical supply and quality control issues research (Phase I) • Overcoming shortage and delays • Phase I study design • Good supply chain management practices for vaccine distribution • Managing sponsors • Managing the vaccines • Operational execution 17:10 Chair’s closing remarks ndrew Nolan A Senior Project Manager Phase I Therapeutic Area Head – Vaccines 17:20 End of Conference Quintiles
  5. 5. Registration Form Vaccine Research & Innovation 2010 2nd – 3rd September 2010 Angel For multiple bookings Pentonville Road Photocopy this form Conf. code VG Vaccine Research & Ci t ty Ro Innovation 2010 ad Standard Prices 2nd - 3rd September 2010 Old Street Conference only Fee: £1299 VAT: £227.33 Total: £1526.33 Old Street Location: SG Conference Centre B Address: 226-236 City Road City Road Promotional Literature Distribution London Distribution of your company’s promotional literature to all conference attendees Fee: £999 VAT: £174.83 Total: £1173.83 Details How to book Forename: Surname: Email: Web: Job Title: Company: UK Office: Tel: +44(0) 20 7336 6100 Main Switchboard Number: Fax: +44(0) 20 7549 9932 Visiongain Ltd BSG House Address: 226-236 City Road London EC1V 2QY UK Country: Postcode: General information Venue: Directions: BSG Conference Centre 226 – 236 City Road, London, EC1V 2TT. United Phone: Fax: Kingdom. Closest tube station is Old Street (Northern Line). Accommodation: Travelodge London City Road Hotel, 7-12 City Road, London, EC1Y 1AE, Tel: 0871 984 6333, Fax: 0207 628 2503, Email: Payment terms: Visiongain require the full amount to be paid before the conference. Visiongain Ltd may refuse entry to delegates who have not paid their invoice in full. A credit card guarantee may Signature: be requested if payment has not been received in full before the event. Visiongain Ltd reserves the right to charge interest on unpaid invoices. I confirm that I have read and agree to the terms and conditions of booking Substitutions/name changes or cancellations: There is a 50% liability on all bookings once made, whether by post, fax, email or web. There is a no refund policy for cancellations received on or Methods of payment after one month before the start of the event. Should you decide to cancel after this date, the full invoice must be paid. Conference notes will then be sent to you. Unfortunately, we are unable to transfer places Payment must be made in sterling between conferences. However, if you cannot attend the conference, you may make a substitution/name change at any time, as long as we are informed in writing by email, fax or post. Name changes and By Mail: Complete and return your signed registration form together with your cheque payable substitutions must be from the same company or organisation and are not transferable between to Visiongain Ltd and send to: visiongain Ltd, BSG House, 226-236 City Road, London, EC1V 2QY, UK countries. Please note that discounted delegates places at a visiongain event are non refundable. By Fax: Complete and fax your signed registration form with your credit card details Invoice alterations: There will be an administration charge of £50 for any changes to an invoice, excluding substitutions/name changes, requested by the customer. This will be charged to the to +44 (0) 20 7549 9932 customer by credit card prior to the changes being made. By Phone: Call us on +44 (0) 20 7336 6100 with your credit card details Indemnity: Visiongain Ltd reserves the right to make alterations to the conference/executive briefing content, timing, speakers or venue without notice. The event may be postponed or cancelled By Credit Card: Fill in your card details below and fax back to +44 (0) 20 7549 9932 due to unforeseen events beyond the control of visiongain Ltd. If such a situation arises, we will try to reschedule the event. However, visiongain Ltd cannot be held responsible for any cost, damage or By Bank Transfer: expenses, which may be incurred by the customer as a consequence of the event being postponed or cancelled. We therefore strongly advise all our conference clients to take out insurance to cover the Visiongain Ltd A/C: visiongain Ltd cost of the registration, travel and expenses. Barclays Bank Sort Code: 20-71-64 Data Protection: Visiongain Ltd gathers and manages data in accordance with the Data Piccadilly Branch Account No: 6038 7118 Protection Act 1988. Your personal information contained in this form may be used to update you on 48 Regent Street Swift Code: BARC GB22 visiongain Ltd products and services via post, telephone, fax or email, unless you state otherwise. We may also share your data with external companies offering complementary products or services. If you London, W1B 5RA IBAN: GB80 BARC 20716460387118 wish for your details to be amended, suppressed or not passed on to any external third party, please send your request to the Database Manager, visiongain Ltd, BSG House, 226-236 City Road, London, Please debit my credit card: EC1V 2QY. Alternatively, you can visit our website at and amend your details. Access MasterCard Visa American Express Please allow approximately 30 days for your removal or update request to be applied to our database. Following your removal or update request, you may receive additional pieces of communication from visiongain Ltd during the transitional period, whilst the changes are coming into effect. Fee: The conference fee includes lunch, refreshments and conference papers provided on the day. Card number: This fee does not include travel, hotel accommodation, transfers or insurance, (which we strongly recommend you obtain). VAT: VAT will be charged at the local rate on each conference. Delegates may be able to recover VAT Expiry Date: incurred by contacting Eurocash Corporation plc +44 (0) 1273 325000, Eurocash specialise in recovering cross-border VAT. Security number (last 3 digits on back of credit card): How we will contact you: Visiongain Ltd’s preferred method of communication is by email and phone. Please ensure that you complete the registration form in full so that we can contact you. Signature: Unable to attend Cardholder’s name: Obviously nothing compares to being there but you need not miss out. Simply tick the box and send with your payment. You will be emailed over the speaker presentations two weeks after the event. Yes please email me the speaker presentations for Price:£550 VAT:£96.25 Total:£646.25 News updates Office use only Please tick if you do not want to receive email news updates in the future